Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
+0.24 (+0.17%)
4:17:10 PM EDT: $144.60 +0.04 (+0.03%)
Products, Regulatory, Other Pre-Announcement

NIH Launches Phase 3 Safety, Efficacy Trial Of 3 Immune Modulator Drugs In Hospitalized Adults With COVID-19

Published: 10/16/2020 11:56 GMT
Johnson & Johnson (JNJ) - Nih - Activ-1 Immune Modulators Trial Expects to Enroll About 2,100 Hospitalized Adults With Covid-19 in U.S. and Latin America.
Nih - Activ-1 Im Trial Aims to Determine If Modulating Certain Immune Response Can Reduce Need for Ventilators & Shorten Hospital Stays.
Nih - Launched Phase 3 Trial to Evaluate Safety & Efficacy of 3 Immune Modulator Drugs in Hospitalized Adults With Covid-19.
Nih - Initial Agents in Activ-1 Im Trial Are Infliximab Developed by Janssen, Abatacept by Bristol Myers Squibb & Cenicriviroc by Abbvie.